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Essentials
• Platelet shape change requires cytoskeletal rearrange-
ment via myosin-mediated actin contraction.
• We investigated whether nitric oxide (NO) affected
thrombin-induced platelet shape change.
• NO inhibits shape change, RhoA/ROCK signalling and
myosin light chain (MLC) phosphorylation.
• NO promotes MLC phosphatase activity, thus prevents
MLC phosphorylation and shape change.
Summary. Background: Platelet shape change, spreading
and thrombus stability require activation of the actin
cytoskeleton contractile machinery. The mechanisms control-
ling actin assembly to prevent unwanted platelet activation
are unclear. Objectives: We examined the effects of nitric
oxide on the signaling pathways regulating platelet actin-
myosin activation. Results: S-nitrosoglutathione (GSNO)
inhibited thrombin-induced platelet shape change and
myosin phosphorylation of the myosin light chain (MLC).
Because thrombin stimulates phospho-MLC through the
RhoA/ ROCK dependent inhibition of MLC phosphatase
(MLCP) we examined the effects of NO on this pathway.
Thrombin caused the GTP loading and activation of
RhoA, leading to the ROCK-mediated phosphorylation of
MLCP on threonine 853 (thr853), which is known to inhibit
phosphatase activity. Treatment of platelets with GSNO
blocked ROCK-mediated increases in phosphoMLCP-
thr853 induced by thrombin. This effect was mimicked by
the direct activator of protein kinase G, 8-pCPT-PET-
cGMP, and blocked by the inhibition of guanylyl cyclase,
but not inhibitors of protein kinase A. Further exploration
of the mechanism demonstrated that GSNO stimulated the
association of RhoA with protein kinase G (PKG) and the
inhibitory phosphorylation (serine188) of RhoA in a
cGMP-dependent manner. Consistent with these observa-
tions, in vitro experiments revealed that recombinant PKG
caused direct phosphorylation of RhoA. The inhibition of
RhoA by GSNO prevented ROCK-mediated phosphoryla-
tion and inhibition of MLCP activity. Conclusions: These
data suggest novel crosstalk between the NO-cGMP-PKG
and RhoA/ROCK signaling pathways to control platelet
actin remodeling.
Keywords: cyclic GMP; myosin light chain phosphatase;
nitric oxide; platelets; protein kinase A; RhoA GTP-biding
protein.
Introduction
Platelets circulate in the blood stream, monitoring vessel
wall integrity. At sites of vascular injury, exposure of pla-
telets to the extra cellular matrix (ECM) proteins collagen
and von Willebrand factor (VWF) leads to platelet adhe-
sion activation and spreading. Platelet activation is a
highly orchestrated process that requires the reorganiza-
tion of the cell cytoskeleton and dramatic morphological
changes that are underpinned by a coordinated response
between signaling molecules and a network of actin-bind-
ing proteins [1]. Foremost amongst these is myosin IIa,
which when phosphorylated on its light chains (MLCs)
can interact directly with actin filaments to drive shape
change. The phosphorylation status of MLCs is con-
trolled through the opposing actions of MLC kinase
(MLCK) and MLC phosphatase (MLCP). Intracellular
Ca2+ mobilization upon platelet activation leads to MLC
phosphorylation at serine 19 (phosphoMLC-ser19) via
MLCK. This phosphorylation intensifies an actomyosin
contractile response that drives platelet adhesion and
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secretion [2,3]. Platelet activation through Ga12/13 protein
coupled receptors (GPCRs) triggers activation of the
small GTPase, RhoA, through membrane localization
and GTP binding [4].
Membrane-bound RhoA associates with, and activates,
Rho-associated, coiled-coil containing protein kinase
(ROCK). A primary target of ROCK signaling is MLCP,
with which it forms a complex to inhibit phosphatase
activity. The outcome of this inhibition is to dynamically
potentiate MLC ser19 phosphorylation because of the
unopposed activity of MLCK. Platelet MLCP is com-
posed of a 38-kD protein phosphatase 1cd (PP1cd) cat-
alytic subunit, a 130-kD myosin-phosphatase targeting
subunit 1 (MYPT1) and a 20-kD regulatory subunit of
unknown function. MYPT1 acts as a molecular scaffold
that localizes the activity of PP1cd to myosin [5]. MYPT1
is targeted by multiple kinases, including ROCK, PKA,
PKG and ILK [6–8]. These kinases potentially target mul-
tiple phosphorylation sites in MYPT-1, indicative of mul-
tiple layers of regulation. The best characterized of these
kinases is ROCK, which induces MYPT1 phosphoryla-
tion on threonine (thr)853 and thr696 associated with inhi-
bition of MLCP activity [9]. Previously, we have shown
that platelet stimulation with thrombin increases MYPT1
thr853 phosphorylation, causes PP1cd disassociation from
MYPT1 and inhibits its activity [10]. However, the mech-
anisms that modulate the inhibitory phosphorylation of
MLCP and help maintain platelets in their quiescent state
remain poorly understood.
Platelet activation is controlled by cyclic nucleotide
signaling pathways downstream of endothelial-derived
nitric oxide (NO) and prostacyclin (PGI2). Cyclic cGMP
and cyclic AMP-dependent kinases have overlapping tar-
get specificity, but also synergise, indicating diversity in
substrate selection [11]. Previously, we have found that
cAMP signaling targets platelet shape change through
regulation of the RhoA/ROCK/MLCP [10]. We have
also demonstrated that NO prevents platelet cytoskeletal
rearrangement in spreading platelets induced by collagen
and VWF that was associated with diminished phospho-
rylation of MLC [12,13], although the mechanism
remained unclear. In the present study we explored the
possibility that cGMP signaling regulated platelets
through a mechanism analogous to cAMP signaling by
targeting MLCP activity. Our data demonstrate that NO
prevents RhoA activation and downstream inhibitory
phosphorylation of MYPT1 to modulate platelet shape
change.
Methods
Reagents
The following antibodies were used: anti-phospho-VASP-
ser239, anti-MYPT1, anti-phospho-MYPT1-thr853 (Cell
Signalling Technology, Hitchin, UK); anti-PKG antibody
(BD Transduction Laboratories, Lexington, KY, USA);
anti-b-tubulin (Upstate Biotechnology, Dundee, UK); and
anti-phospho-RhoA-ser188 (Santa Cruz, Calne, UK).
Y27632, 1,2-bis-(o-aminophenoxy) ethane-tetra-acetic acid
tetra-(acetoxymethyl) ester (BAPTA-AM) was from Cal-
biochem (Nottingham, UK). 8-(4-Chlorophenylthio)ade-
nosine-30,50-cyclic monophosphorothioate, Rp-isomer
(Rp-8-CPT-cAMPS) and 8-(4-Chlorophenylthio)-ß-phe-
nyl-1, N²- ethenoguanosine-30, 50-cyclic monophosphate
(8-pCPT-PET-cGMP) were from Biolog (Breman, Ger-
many). RhoA pull-down kit was from Cytoskeleton
(Peterborough, UK). Para-nitrophenyl phosphate was
from New England Biolabs (Hitchen, UK). All other
reagents were obtained from Sigma Ltd (Poole, UK).
Platelet isolation
Human blood was taken from drug-free volunteers into
acid citrate dextrose (29.9 mM Na3C6H5O7, 113.8 mM glu-
cose, 72.6 mM NaCl and 2.9 mM citric acid, pH 6.4). Plate-
let-rich plasma (PRP) was obtained by centrifugation of
whole blood at 200 9 g at 20 °C for 20 min. PRP was trea-
ted with citric acid (0.3 mM) and indomethacin (20 lM) and
centrifuged at 800 9 g for 12 min. The platelet pellet was
then suspended in wash buffer (36 mM citric acid, 10 mM
EDTA, 5 mM glucose, 5 mM KCl, 9 mM NaCl) and cen-
trifuged at 800 9 g for 12 min. Platelets were resuspended
(3 9 108 platelets mL!1) in modified Tyrode’s buffer
(150 mM NaCl, 5 mM HEPES [N-2-hydroxyethylpipera-
zine-N0-2-ethanesulfonic acid], 0.55 mM NaH2PO4, 7 mM
NaHCO3, 2.7 mM KCl, 0.5 mM MgCl2, 5.6 mM glucose,
pH 7.4) supplemented with apyrase (2U mL!1), indo-
methacin (10 lM) or EGTA (1 mM) unless otherwise stated.
Platelet shape change
Washed platelets (2.5 9 108 platelets mL!1) were pre-
incubated with EGTA (1 mM), apyrase (2 U mL!1) and
indomethacin (10 lM). S-nitrosoglutathione (GSNO) (0.1–
20 lM) was added to platelets for 2 min prior to stimula-
tion with thrombin (0.05 U mL!1) and shape change
recorded as previously described [10,12].
cAMP measurement
Washed platelets (2 9 108 platelets mL!1) were treated
with PGI2 for 1 min or GSNO for 2 min at indicated
concentrations and reactions were terminated by addition
of ice-cold lysis buffer. cAMP levels were assayed with a
commercially available enzyme immunoassay system fol-
lowing the manufacturer’s instructions.
RhoA Pull-down assay
Washed platelets (5 9 108 platelets mL!1) were treated
with thrombin, in the presence and absence of GSNO
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(10 lM), at 37 °C with stirring for 1 min before stopping
the reaction with an equal volume of lysis buffer. Lysates
(300 lg) were incubated for 90 min at 4 °C with Rhote-
kin-RBD-beads (25 lg). Bead pellets were washed once
and Laemmeli buffer was added prior to immunoblotting.
In vitro kinase assay
Recombinant human full-length active PKG was incu-
bated with recombinant human His tagged-RhoA (55 ng)
in kinase buffer (25 mM MOPS, pH7.2, 12.5 mM glycerol-
2-phosphate, 25 mM MgCl2, 5 mM EGTA, 2 mM EDTA
and 0.25 mM DTT) supplemented with ATP (400 lM) at
37 °C for 15 min. The reaction was stopped by addition
of Laemmli buffer to the mixture for further immunoblot
analysis.
Immunoprecipitation and immunoblotting
Washed platelets (8 9 108 platelets mL!1) were treated
with thrombin, in the presence or absence of GSNO, and
incubated at 37 °C with stirring for the appropriate time.
Reactions were stopped by addition of an equal volume
of ice-cold lysis buffer (150 mM NaCl, 10 mM Tris,
1 mM EDTA, 1 mM EGTA, 1% Igepal, 1 mM phenyl-
methanesulfonyl fluoride, 2.5 mM Na3VO4, phosphatase
cocktail inhibitor, protease cocktail inhibitor, pH7.4).
Lysates were incubated overnight at 4 °C with anti-PKG
(1 lg) or IgG control antibodies, with constant rotation
in the presence of protein A Sepharose beads. To prepare
whole cell lysates platelets were then treated with the
appropriate reagents before termination of the reactions
with Laemmli buffer. Immunoprecipitates or lysates were
separated by SDS-PAGE and analysed by immunoblot-
ting as previously described [14]. The following primary
antibodies were used: anti-phospho-VASP-ser239, anti-
phospho-RhoA-ser188 (both 1 : 1000), anti-RhoA and
anti-phospho-MYPT1-thr853 (both 1 : 250).
Measurement of myosin phosphatase activity
Myosin phosphatase activity was determined as previ-
ously described [15]. PP1d was immunoprecipitated using
anti-PP1d antibody from unstimulated platelets or plate-
lets stimulated with thrombin in the presence or absence
of GSNO. Immunoprecipitated PP1d was incubated for
1 h at room temperature (RT) with 5 mM pNPP in
100 lL reaction buffer (4 mM Tris-base, 2 mM KCl, 3 mM
MgCl2, 0.1 mM MnCl2, 0.1 mg ml
!1 BSA, 2 mM DTT,
pH8.1). The reaction was stopped with 5 mM NaOH and
absorbance was measured at 405 nm. Specific PP1d
activity was obtained by subtracting the activity in the
non-immune IgG IP from the activity in the PP1d IP. To
verify that each sample had equal amounts of PP1d,
samples were collected post-assay and analysed by
immunoblotting for total PP1d.
Measurement of intracellular calcium flux
Washed platelets (1 9 108 platelets mL!1) were loaded
with the fluorescent probe Fura-3,AM at 37 °C for
30 min in the dark. Subsequently, platelets were washed
with modified Tyrode’s buffer and resuspended at
1 9 106 platelets mL!1. Two mL of platelets were trans-
ferred into a quartz cuvette, which was placed in a lumi-
nescence spectrometer (Photon Technology International,
Edison, NJ, USA). Calcium flux was measured by record-
ing the ratio of fluorescence emitted at 530 nm after
sequential excitation at 340 and 380 nm and expressed as
fluorescence intensity (counts per second).
Statistical analysis
Results are expressed as means " SEM and statistical
analyses were undertaken using Prism 6.0 (GraphPad, La
Jolla, CA, USA). Differences between samples were deter-
mined using unpaired Student’s t-test. The results were
considered significant when P values were < 0.05.
Results
S-nitrosoglutathione inhibits shape change and
phosphorylation of MLC induced by thrombin
Platelet shape change is the earliest functional response
following activation and is associated with cytoskeletal
rearrangement. Under conditions that abrogated the
effects of secondary signaling through ADP, TxA2 and
integrins, thrombin (0.05 U mL!1) induced platelet
shape change (Fig. 1A), which was associated with
increased phosphorylation of MLC at serine19 (phos-
pho-MLC-ser19) (Fig. 1B). When platelets were treated
with GSNO (0.01–10 lM) prior to stimulation with
thrombin, shape change was modulated and abolished at
10 lM (Fig. 1A). GSNO also caused a significant con-
centration-dependent inhibition of MLC phosphorylation
(Fig. 1B). The inhibition of phosphorylation was evident
at 2 min and was maintained for up to 60 min
(Fig. 1C). To verify that the effect of NO on shape
change was not specific to thrombin only, we also per-
formed similar experiments in the absence of apyrase
and indomethacin. Thrombin induced platelet shape
change that was associated with an increase in MLC
phosphorylation (Figure S1Ai). Pretreatment of platelets
with GSNO caused an inhibition of platelet shape
change and MLC phosphorylation (Figure S1Aii).
Hence, NO inhibits shape change and MLC phosphory-
lation under conditions where all three agonists known
to drive these responses are present [16,17].
Our previous work and that of others has shown that
these concentrations of GSNO cause a rapid increase in
cGMP [13]. We next examined the role of both cAMP
and cGMP signaling downstream of GSNO treatment. In
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the first instance, blocking sGC with ODQ [18] abolished
the ability of GSNO to inhibit phosphorylation of MLC
(Fig. 2A). By contrast, the effect of GSNO on (phospho-
MLC-ser19) was maintained in the presence of PKA inhi-
bitor Rp-8-CPT-cAMPS (250 lM) [19] (Fig. 2A). Similar
results were obtained with KT-5720 (20 lM), a struc-
turally diverse PKA inhibitor (not shown). These inhibi-
tors blocked the phosphorylation of vasodilator-activated
phosphoprotein (VASP) serine157 induced by PGI2, con-
firming their specificity in platelets (Figure S1). In the sec-
ond instance we used 8-pCPT-PET-cGMP (5 lM) as a
cell-permeable activator of PKG that shows little cross-
reactivity with cAMP signaling [20]. The cGMP analogue
inhibited thrombin-induced MLC phosphorylation, which
was unaffected by both ODQ and inhibitors of PKA
(Fig. 2B). Importantly, ODQ also prevented GSNO from
inhibiting thrombin-induced shape change (Fig. 2C).
Thus, GSNO (10 lM) abolished thrombin-induced shape
change and MLC phosphorylation through a mechanism
that involves cGMP signaling.
GSNO targets both Ca2"-dependent and RhoA/Rho kinase
pathways activated by thrombin
Several studies, including our own, have shown that
thrombin stimulates shape change and phosphorylation of
MLC through both Ca2+-dependent and RhoA/ROCK
(Ca2+-independent) dependent pathways [10,14,21]. We
have previously shown that cAMP signaling targets both
of these pathways independently of each other [10] and
wished to determine whether the same was true for
cGMP. To achieve this we used BAPTA-AM to chelate
intracellular Ca2+ and the ROCK inhibitor Y27632
(10 lM) [22]. We hypothesized that using these inhibitors
alone and in combination with GSNO would allow us to
determine which pathways were targeted by cGMP signal-
ing. Thrombin (0.05 U mL!1) induced shape change was
partially inhibited by BAPTA-AM (20 lM) alone and
Y27632 (10 lM) alone, but ablated when they were used
in combination. Next, we treated platelets with BAPTA-
AM (20 lM) alone and stimulated with thrombin; we
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Fig. 1. Nitric oxide (NO) regulates thrombin-induced platelet shape change and myosin light chain (MLC) phosphorylation. (A) Washed plate-
lets (3 9 108 platelets per milliliter) were preincubated with apyrase (2 U mL!1), indomethacin (10 lM) and EGTA (1 mM), followed by stimu-
lation with thrombin (0.05 U mL!1) in the presence and absence of GSNO (0.01–20 lM) and traces recorded for 1 min. (B) Washed platelets
(3 9 108 platelets per milliliter) were stimulated with thrombin (0.05 U mL!1) for 1 min in the presence or absence of GSNO (0.01–40 lM)
and phospho-MLCser19 was assessed by immunoblotting. (C) Washed platelets (3 9 108 platelets per milliliter) were treated with GSNO 10 lM
for up to 60 min prior to stimulation with thrombin (0.05 U mL!1) for 1 min and phospho-MLCser19 was assessed by immunoblotting.
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reasoned that under these conditions only the ROCK
pathway would be active, allowing examination of the
effects of cGMP on ROCK signaling in isolation.
BAPTA-AM alone reduced shape change, but this was
abolished in combination with GSNO (Fig. 3A). Inhibi-
tion of the ROCK pathway with Y27632 (10 lM) was
then used to study the effects of cGMP on the isolated
Ca2+-dependent pathway. Under these conditions shape
change was again reduced but not blocked (Fig. 3A),
whereas the combination of Y27632 and GSNO also
abolished shape change (Fig. 3A).
To confirm that the effects on shape change occurred
through the regulation of myosin IIa we next examined the
phosphorylation of MLC. Thrombin-induced phos-
phoMLCser19 was partially, but significantly, inhibited by
both BAPTA-AM (20 lM) alone and Y27632 (10 lM)
alone. The phosphorylation was abolished when the inhibi-
tors were used in combination. Consistent with the shape
change experiments we found that when GSNO (10 lM)
was used in combination with either of the inhibitors the
phosphorylation was ablated (Fig. 3B). These data suggest
that cGMP signaling targets both the RhoA/ROCK and
Ca2+-dependent pathways independently of each other to
modulate platelet function. To determine whether GSNO
inhibits Ca2+-dependent signaling, we measured Ca2+ flux
in thrombin-stimulated platelets. Treatment of platelets
with BAPTA-AM resulted in a concentration-dependent
inhibition of thrombin-induced MLC phosphorylation
(Figure S1C). The highest concentration used (20 lM)
also led to intracellular Ca2+ chelation. Consistent with
this, and in agreement with previous reports [23,24],
treatment of platelets with GSNO significantly inhibited
thrombin-induced Ca2+ flux (Figure S1D).
GSNO inhibits thrombin-induced activation of RhoA
In the next series of experiments we examined the effects
of cGMP signaling on the RhoA/ROCK-dependent sig-
naling pathway. We first investigated if cGMP signaling
targeted RhoA directly using a GTP-RhoA pull-down
assay [25]. Thrombin (0.05 U mL!1) elevated the levels of
GTP-bound RhoA (Fig. 4A), which was abolished if pla-
telets were pretreated with GSNO (10 lM). To confirm
that our observation was cGMP mediated, we show that
the inhibition of RhoA activation by GSNO was
prevented by the sGC inhibitor ODQ (Fig. 4A). In con-
trast, Y27632 and BAPTA-AM had no effect on RhoA
activation (data not shown), indicating that cGMP signal-
ing targets RhoA activation independently of any poten-
tial effects on ROCK activity and Ca2+ flux. The
phosphorylation of RhoA on serine188 negatively regu-
lates RhoA activity either through the inhibition of the
GTPase activation or prevention of its membrane com-
partmentalization. Because PKG can phosphorylate
RhoA in vitro [26], we hypothesized that PKG-mediated
phosphorylation of RhoA may account, at least in part,
for the inhibition of RhoA by cGMP signaling. GSNO
(0–10 lM) induced a concentration-dependent increase in
phospho-RhoA-ser188, with maximal phosphorylation
observed at 10 lM (Fig. 4B). Phosphorylation of RhoA in
response to GSNO occurred within 60 s and was main-
tained for 60 min (longest time tested) (Fig. 4C). In com-
parison, the phosphorylation of VASP-ser239 returned to
basal after 45 min, suggesting that the phosphorylation of
RhoA that was maintained for significantly longer may
be regulated in a distinct manner.
Previously we demonstrated that RhoA can be targeted
by cAMP signaling. Because several studies have sug-
gested that NO can signal through both cAMP and
cGMP-dependent pathways [27], it was important to clar-
ify which pathway was responsible. To dissect which
pathway downstream of NO controlled RhoA activity we
used a multi-layered approach. Firstly, we measured
intracellular cAMP levels in platelets treated with either
PGI2 or GSNO. PGI2 (50 nM) at a concentration we have
shown to induce RhoA phosphorylation caused a signifi-
cant increase in cAMP concentrations to 2117 " 363
fmol/108 platelets (P = 0.004 vs. basal). By contrast,
Fig. 2. Nitric oxide (NO) inhibits myosin light chain (MLC) phos-
phorylation in a cGMP-dependent manner and not cAMP-dependent
manner. Washed platelets (3 9 108 platelets per milliliter) were stim-
ulated with thrombin (0.05 U mL!1) for 1 min in the presence or
absence of GSNO (10 lM) (A) or 8-pCPT-PET-cGMP (5 lM) (B),
ODQ (20 lM) and Rp-8-CPT-cAMPS (250 lM) and phospho-
MLCser19 was assessed by immunoblotting. (i) Representative immu-
noblots from four independent experiments. (ii) Densitometry of
MLCser19 phosphorylation from four different experiments. (C)
Washed platelets (3 9 108 platelets per milliliter) were preincubated
with apyrase (2 U mL!1), indomethacin (10 lM) and EGTA (1 mM),
followed by stimulation with thrombin (0.05 U mL!1) in the pres-
ence and absence of GSNO (10 lM) and ODQ (20 lM).
© 2017 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals, Inc. on behalf of International Society on Thrombosis and Haemostasis.
1672 A. Aburima et al
GSNO (10 lM) did not increase cAMP levels (141 " 29
fmol/108 platelets, P = 0.3 vs. basal) above basal levels
(Fig. 5A). Secondly, the sGC inhibitor ODQ (20 lM), but
not the PKA inhibitors Rp-8-CPT-cAMPS (250 lM) and
KT-5720 (20 lM) (not shown), prevented the phosphory-
lation of RhoA by GSNO (10 lM) (Fig. 5B). Thirdly
GSNO-induced RhoA phosphorylation was reproduced
by 8-pCPT-PET-cGMP (5 lM), which caused a significant
phosphorylation of RhoA (Fig. 5C), which as expected
was resistant to both sGC and PKA inhibitors. Together
these data suggest that GSNO-induced RhoA phosphory-
lation is likely to be cAMP independent. In a fourth ser-
ies of experiments we explored the potential role of PKG
in the phosphorylation of RhoA. Immunoprecipitation of
RhoA from platelets demonstrated that the PKG is asso-
ciated with RhoA when platelets are treated with GSNO
(Fig. 5D), suggesting that RhoA could be a direct target
for PKG in platelets. Finally, to confirm that this associa-
tion under physiological conditions could lead to the
phosphorylation of RhoA by PKG, we performed an
in vitro kinase assay. Incubation of recombinant human
RhoA with recombinant active PKG resulted in the phos-
phorylation of RhoA on serine188 (Fig. 5E).
GSNO modulates the inhibitory phosphorylation of MYPT1
by ROCK
ROCK is a downstream effector of RhoA that is proposed
to drive platelet shape change and secretion through inhibi-
tion of MLCP [2]. Having established that cGMP signaling
phosphorylated and inhibited RhoA, we examined how
this influenced downstream signaling events. We first
examined the effects of GSNO on MLCP activity through
the immunoprecipitation of the PP1d subunit using a well-
established approach [2]. Immunoprecipitation of PP1d
demonstrated a basal activity of myosin phosphatase,
which was reduced significantly when platelets were stimu-
lated with thrombin (1 " 0.0 to 0.5 " 0.08, P = 0.006 vs.
basal). Pretreatment with GSNO prevented the inhibition
of MLCP activity by thrombin, with activity remaining at
basal levels (1.06 " 0.03, P = 0.004 vs. thrombin)
(Fig. 6A). ROCK inhibits MLCP through the phosphory-
lation of MYPT1 on thr696 and thr853, the targeting subunit
of MLCP, which inhibits the phosphatase [10]. We used
the phosphorylation of the best-characterized site, thr853,
as a marker of ROCK activity. The ability of GSNO to
inhibit ROCK-mediated phosphorylation of MYPT1-
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Fig. 3. Nitric oxide (NO) inhibits platelet shape change and myosin light chain (MLC) phosphorylation by targeting Ca2+ and RhoA/ROCK
pathways. (A) Washed platelets (3 9 108 platelets per milliliter) were preincubated with apyrase (2 U mL!1), indomethacin (10 lM) and EGTA
(1 mM), followed by stimulation with thrombin (0.05 U mL!1) in the presence and absence of GSNO (10 lM), Y27632 (10 lM) and BAPTA-
AM (20 lM) and traces recorded for minute. (B) As in (A) except that phospho-MLCser19 was assessed by immunoblotting. [Color figure can
be viewed at wileyonlinelibrary.com]
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thr853 was evident at 1 lM but maximal at 10 lM (Fig. 6B).
Using this same concentration of the NO donor we
observed that the inhibition began within 30 s of exposure
to GSNO and was maintained for 60 min (longest time
tested) (Fig. 6C). Importantly, MYPT1-thr853 phosphory-
lation was abolished by Y27632, but not by BAPTA-AM
(Fig. 6D), confirming the role of ROCK. The ability of
GSNO to inhibit phosphorylation of MYPT1-thr853 was
prevented by ODQ (Fig. 6E), consistent with the require-
ment for cGMP. To verify the role of PKG, experiments
were repeated in the presence of the PKA inhibitor Rp-8-
CPT-cAMPS, which has no effect on GSNO-mediated
inhibition of MYPT phosphorylation.
Discussion
Platelet actin polymerisation is required for platelet shape
change, secretion and stability of thrombi under flow.
Understanding the mechanisms that control the polymeri-
sation is critical to understanding how effective hemosta-
sis is maintained. The small GTPase RhoA is crucial to
these events, as exemplified by the platelet deficient in
RhoA, which show altered shape change and function
[28]. Previously we have shown that PGE1 inhibits plate-
let shape change by targeting the RhoA/ROCK pathway
in a PKA-dependent manner [10]. In the present study we
expand these initial observations to demonstrate that
cGMP signaling also targets RhoA to prevent inhibition
of MLCP (disinhibition) and control MLC phosphoryla-
tion, suggesting that RhoA is a critical node for cyclic
nucleotide-mediated inhibition of platelets.
We found that treatment of platelets with GSNO caused
the ablation of shape change under stirring conditions,
consistent with previous observations showing that NO
prevents platelet spreading [29]. This was mirrored by the
inhibition of MLC phosphorylation, a key event in actin
polymerisation. Shape change and the associated phospho-
rylation of MLC are driven through both Ca2+-dependent
and independent pathways, and although we and others
have established the effects of NO on Ca2+ signaling, our
knowledge of inhibitory mechanisms by which NO inhibits
platelets independently of effects on Ca2+ is unclear. Using
BAPTA-AM to isolate RhoA/ROCK signaling we found
that NO abolished both shape change and MLC phospho-
rylation driven by RhoA signaling. NO inhibited throm-
bin-induced intracellular Ca2+ flux to levels similar to the
chelator BAPTA-AM. We could confirm that NO targeted
RhoA directly because RhoA pull-down assays demon-
strated that NO blocked the activation of RhoA upstream
of ROCK. NO inhibits platelet function in a cGMP-depen-
dent manner, evident by the lack of inhibition in GCKO
platelets [30]. However, cGMP-independent mechanisms
have also been documented [29], including through cAMP-
dependent signaling and S-nitrosylation [31].
Of particular interest was the potential role of cAMP,
which we have also shown to target RhoA signaling [10].
NO-induced cGMP has been proposed to inhibit PDE3A,
leading to accumulation of cAMP and activation of PKA
[32]. Indeed, one study has shown that NO-induced phos-
phorylation of VASP, a substrate for both PKA and
PKG, was entirely dependent on PKA signaling [33].
Given this crosstalk between cyclic nucleotide signaling, it
was possible that NO could inhibit RhoA activation
through cAMP/PKA signaling. To dissect the cGMP-
dependent and independent effects of NO on platelet
shape change, we used the established sGC inhibitor
GSNO (10 µM)
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ODQ [18]. Thrombin-induced platelet shape change,
RhoA activation and MLC phosphorylation were inhib-
ited by GSNO, which in turn was prevented by the pres-
ence of ODQ, suggesting a cGMP-dependent pathway.
Given that cGMP could induce cAMP formation through
inhibition of PDE3A, we measured cAMP concentrations
in response to GSNO. Using a concentration of NO
donor that completely inhibited RhoA activation, we
found no significant increase in cAMP concentrations.
Given newer models of cAMP signaling, it was also possi-
ble that a localized cAMP response [34–36], which would
not be detected using cAMP measurement in platelet
lysates, could have occurred, leading to PKA activation.
To account for this we examined the ability of GSNO
to induce phosphorylation of RhoA and prevent the inhi-
bitory phosphorylation of MYPT-1 in the presence of
established PKA inhibitors. These inhibitors did not influ-
ence the actions of GSNO, suggesting strongly that
cAMP/PKA signaling was not required for the actions of
GSNO. Having excluded a role for PKA signaling, we
characterized the potential role of cGMP signaling. Given
the lack of specific cell-permeable PKG inhibitors with
reasonable potency [37], we confirmed the role of cGMP
by using the membrane-permeable cGMP analog (8-
pCPT-PET-cGMP). This agent served two purposes, both
confirming a role for cGMP and acting as direct activator
of PKG. Consistent with GSNO, 8-pCPT-PET-cGMP
inhibited MLC phosphorylation and induced inhibitory
phosphorylation of RhoA, actions that were unaffected
by ODQ or PKA inhibitors. Although the pharmacologi-
cal interventions were strongly suggestive of a key role
for PKG, we went on to confirm the potential interac-
tions of PKG and RhoA. The immunoprecipitation of
RhoA revealed association of PKG with RhoA in
response to GSNO. Although this does not prove that
PKG phosphorylates RhoA, results from an in vitro PKG
kinase assay showed that RhoA can be phosphorylated
by PKG in the absence of other mediators.
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MLCP plays a key role in the regulation of actin poly-
merisation [38]. The phosphorylation of the MYPT-1 scaf-
folding component of this complex by multiple kinases
controls its localization and activity through the formation
of macromolecular complexes. Stimulation with thrombin
causes ROCK-mediated inhibitory phosphorylation and
disruption of the haloenzyme structure. Our current and
previous data suggest that cyclic nucleotide-dependent
kinases, PKG and PKA, inhibit RhoA activation as a
mechanism to prevent inhibition of MLCP, a process ter-
med disinhibition. The fact that both kinases have the
capacity to target RhoA signaling suggests that inhibition
of this pathway is critical to their ability to modulate plate-
let function. What is still unclear is whether in vivo there is
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a mechanism that allows PKG and PKA to differentially
target RhoA, which could be either context or location
dependent. Furthermore, it is known that PKA and PKG
can phosphorylate MYPT-1 directly in smooth muscle cells
[39,40], which may provide an additional and coordinated
mechanism to control MLC phosphorylation; this requires
further investigation. Given the emerging roles of AKAPs
and the concept of spatiotemporal control of cyclic nucleo-
tide signaling [35], it is also possible that PKA and PKG
target individual pools of RhoA and ROCK. This issue of
the compartmentalization of cyclic nucleotide signaling in
platelets requires further exploration.
In conclusion, NO-induced cGMP signaling modulated
RhoA/ROCK signaling in platelets, leading to the disinhi-
bition of MLCP to control the phosphorylation of MLC.
The identification of RhoA as a new target for cGMP sig-
naling provides a novel mechanism of platelet inhibition
by NO and adds to the increasing complexity of inhibi-
tory signaling in blood platelets.
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